Loading company…
Simnova develops CAR-NK and CAR-T cell therapies for hematologic malignancies and solid tumors.
Established in 2019 in Shanghai, Simnova develops cell therapies for cancer, including CAR-NK and CAR-T programs. It was affiliated with Simcere Group before becoming independent in 2021; its first allogeneic CAR-NK product entered clinical stage in 2022. In August 2026, it raised approximately CNY 400 million in Series B funding co-led by Fortera Capital, Cenova Ventures, and Pudong Venture Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in